Cargando…
Multiple neoplasms, single primaries, and patient survival
BACKGROUND: Multiple primary neoplasms in surviving cancer patients are relatively common, with an increasing incidence. Their impact on survival has not been clearly defined. METHODS: This was a retrospective review of clinical data for all consecutive patients with histologically confirmed cancer,...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949559/ https://www.ncbi.nlm.nih.gov/pubmed/24623992 http://dx.doi.org/10.2147/CMAR.S57378 |
_version_ | 1782306908844064768 |
---|---|
author | Amer, Magid H |
author_facet | Amer, Magid H |
author_sort | Amer, Magid H |
collection | PubMed |
description | BACKGROUND: Multiple primary neoplasms in surviving cancer patients are relatively common, with an increasing incidence. Their impact on survival has not been clearly defined. METHODS: This was a retrospective review of clinical data for all consecutive patients with histologically confirmed cancer, with emphasis on single versus multiple primary neoplasms. Second primaries discovered at the workup of the index (first) primary were termed simultaneous, if discovered within 6 months of the index primary were called synchronous, and if discovered after 6 months were termed metachronous. RESULTS: Between 2005 and 2012, of 1,873 cancer patients, 322 developed second malignancies; these included two primaries (n=284), and three or more primaries (n=38). Forty-seven patients had synchronous primaries and 275 had metachronous primaries. Patients with multiple primaries were predominantly of Caucasian ancestry (91.0%), with a tendency to develop thrombosis (20.2%), had a strong family history of similar cancer (22.3%), and usually presented with earlier stage 0 through stage II disease (78.9%). When compared with 1,551 patients with a single primary, these figures were 8.9%, 15.6%, 18.3%, and 50.9%, respectively (P≤0.001). Five-year survival rates were higher for metachronous cancers (95%) than for synchronous primaries (59%) and single primaries (59%). The worst survival rate was for simultaneous concomitant multiple primaries, being a median of 1.9 years. The best survival was for patients with three or more primaries (median 10.9 years) and was similar to the expected survival for the age-matched and sex-matched general population (P=0.06991). CONCLUSION: Patients with multiple primaries are usually of Caucasian ancestry, have less aggressive malignancies, present at earlier stages, frequently have a strong family history of similar cancer, and their cancers tend to have indolent clinical behavior with longer survival rates, possibly related to genetic predisposition. |
format | Online Article Text |
id | pubmed-3949559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39495592014-03-12 Multiple neoplasms, single primaries, and patient survival Amer, Magid H Cancer Manag Res BACKGROUND: Multiple primary neoplasms in surviving cancer patients are relatively common, with an increasing incidence. Their impact on survival has not been clearly defined. METHODS: This was a retrospective review of clinical data for all consecutive patients with histologically confirmed cancer, with emphasis on single versus multiple primary neoplasms. Second primaries discovered at the workup of the index (first) primary were termed simultaneous, if discovered within 6 months of the index primary were called synchronous, and if discovered after 6 months were termed metachronous. RESULTS: Between 2005 and 2012, of 1,873 cancer patients, 322 developed second malignancies; these included two primaries (n=284), and three or more primaries (n=38). Forty-seven patients had synchronous primaries and 275 had metachronous primaries. Patients with multiple primaries were predominantly of Caucasian ancestry (91.0%), with a tendency to develop thrombosis (20.2%), had a strong family history of similar cancer (22.3%), and usually presented with earlier stage 0 through stage II disease (78.9%). When compared with 1,551 patients with a single primary, these figures were 8.9%, 15.6%, 18.3%, and 50.9%, respectively (P≤0.001). Five-year survival rates were higher for metachronous cancers (95%) than for synchronous primaries (59%) and single primaries (59%). The worst survival rate was for simultaneous concomitant multiple primaries, being a median of 1.9 years. The best survival was for patients with three or more primaries (median 10.9 years) and was similar to the expected survival for the age-matched and sex-matched general population (P=0.06991). CONCLUSION: Patients with multiple primaries are usually of Caucasian ancestry, have less aggressive malignancies, present at earlier stages, frequently have a strong family history of similar cancer, and their cancers tend to have indolent clinical behavior with longer survival rates, possibly related to genetic predisposition. Dove Medical Press 2014-03-05 /pmc/articles/PMC3949559/ /pubmed/24623992 http://dx.doi.org/10.2147/CMAR.S57378 Text en © 2014 Amer. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Amer, Magid H Multiple neoplasms, single primaries, and patient survival |
title | Multiple neoplasms, single primaries, and patient survival |
title_full | Multiple neoplasms, single primaries, and patient survival |
title_fullStr | Multiple neoplasms, single primaries, and patient survival |
title_full_unstemmed | Multiple neoplasms, single primaries, and patient survival |
title_short | Multiple neoplasms, single primaries, and patient survival |
title_sort | multiple neoplasms, single primaries, and patient survival |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949559/ https://www.ncbi.nlm.nih.gov/pubmed/24623992 http://dx.doi.org/10.2147/CMAR.S57378 |
work_keys_str_mv | AT amermagidh multipleneoplasmssingleprimariesandpatientsurvival |